Bial

Bial is a Portuguese pharmaceutical company headquartered in São Mamede do Coronado, in the municipality of Trofa, Porto District. Established in 1924, it is one of Portugal's largest pharmaceutical businesses and has developed from a domestic medicines company into an internationally active research and commercialization organization. Its products have been distributed through pharmacies in more than 58 countries spanning Europe, the Americas, Africa, and Asia. The company’s principal research interests have included the central nervous system, cardiology, and allergen immunotherapy. This focus has produced a portfolio that includes medicines for epilepsy and Parkinson’s disease, as well as clinical-stage and exploratory compounds directed at sympathetic nervous-system activity and the endocannabinoid system. Bial has combined internal discovery and development with licensing and commercialization partnerships, allowing selected products to reach markets through larger international pharmaceutical companies. A significant development in Bial’s international pharmaceutical activities was the clinical development of eslicarbazepine acetate, an antiseizure medicine for adjunctive treatment of partial-onset seizures in adults. After Bial completed its clinical evaluation in 2008, Eisai obtained exclusive European rights to market, promote, and distribute the medicine under names including Zebinix and Exalief. In the United States, Sunovion commercialized the product as Aptiom. This arrangement illustrated Bial’s use of regional licensing partnerships to expand the reach of medicines originating from its research program. Bial also developed opicapone, a catechol-O-methyltransferase inhibitor intended for use in Parkinson’s disease. Other research programs identified in public descriptions of the company include etamicastat and BIA 5-1058, both dopamine-beta-hydroxylase inhibitors designed to reduce peripheral norepinephrine activity without comparable effects in the brain. The company has also pursued allergen immunotherapy and has entered inbound licensing arrangements, including a 2015 agreement with Helsinn Group concerning anamorelin distribution and licensing rights in Spain, Portugal, Angola, and Mozambique. Research investment has been supported by external financing. In September 2015, the European Investment Bank agreed to provide €45 million for Bial’s research and development program over a three-year period. The financing was directed toward therapeutic research in the central nervous system, cardiology, and allergen immunotherapy. The European Investment Bank stated that Bial did not have the status of a contracting entity for the relevant purpose and therefore was not subject to European Union public-procurement rules in connection with the agreement. Bial’s history also includes a serious clinical-trial event involving BIA 10-2474, an experimental fatty-acid amide hydrolase inhibitor. A phase-one study conducted by Biotrial in Rennes in 2015 and 2016 was suspended after participants receiving repeated doses developed severe neurological effects; one participant later became brain-dead and other participants were hospitalized. The event led to regulatory and public scrutiny of the trial’s design, conduct, dose escalation, and oversight. It remains one of the most consequential episodes associated with the company, although it concerned an experimental compound rather than an approved commercial medicine. Bial continues to represent Portugal’s internationally oriented pharmaceutical sector, with activities spanning drug discovery, clinical development, licensing, regulatory work, and international commercialization. Its public profile combines a long domestic history with a comparatively focused research strategy centered on neurological and related therapeutic areas.

Bial was founded in Portugal in 1924 and developed into one of the country’s major pharmaceutical companies. Its base in São Mamede do Coronado, in the Porto District, became the center of a business that combined pharmaceutical manufacturing and commercialization with progressively more ambitious research and development. Over time, Bial expanded beyond the Portuguese market, making its medicines available through pharmacy channels in more than 58 countries across four continents. The company’s research direction has been concentrated in areas where specialist pharmaceutical development can create differentiated products, especially the central nervous system, cardiology, and allergen immunotherapy. This strategy has included both approved or commercialized medicines and earlier-stage discovery programs. A notable early international success was eslicarbazepine acetate, developed as an adjunctive treatment for partial seizures in adults with epilepsy. Bial completed its clinical evaluation in 2008. Rather than commercializing the product globally through its own sales organization, Bial used regional licensing: Eisai received exclusive rights in Europe, where the medicine was sold under names including Zebinix and Exalief, while Sunovion marketed it in the United States as Aptiom. Pediatric development was pursued, while a separate investigation into diabetic neuropathic pain was stopped early. Bial’s second major pharmaceutical development identified in the historical record was opicapone, also known as BIA 9-1067. It is a COMT inhibitor developed for Parkinson’s disease, reflecting the company’s emphasis on neurological disorders. Bial’s research portfolio also included etamicastat, a dopamine-beta-hydroxylase inhibitor intended to lower norepinephrine levels in peripheral sympathetically innervated tissues without affecting the brain, and BIA 5-1058, another reversible inhibitor designed around a similar peripheral mechanism. These programs demonstrate the company’s interest in pharmacology that could influence cardiovascular and autonomic functions while limiting central nervous system exposure. To support this research-led model, Bial obtained substantial institutional financing. In September 2015, the European Investment Bank signed a €45 million agreement to fund Bial research and development over the following three years. The stated areas were central nervous system disease, cardiology, and allergen immunotherapy. The EIB also determined that Bial was not a contracting entity for the relevant legal purpose, meaning the company was not subject to European Union public-procurement rules in connection with the financing arrangement. Bial supplemented internal research with external licensing and distribution relationships. In September 2015, it entered an agreement with the Helsinn Group covering exclusive distribution and licensing rights for anamorelin in Spain, Portugal, Angola, and Mozambique. Such arrangements allowed Bial to add selected medicines to its regional portfolio while using partnerships to broaden the commercial reach of its own discoveries. The company became the subject of extensive scrutiny following the development of BIA 10-2474, an experimental FAAH inhibitor affecting the endocannabinoid system. Bial commissioned the contract research organization Biotrial to conduct a phase-one study in Rennes, France. The study began in July 2015 and initially evaluated single doses in adult male and female volunteers. On 7 January 2016, a multiple-dose phase began with six participants who were not receiving placebo. The first participant to receive repeated dosing was hospitalized at Rennes University Hospital on 10 January. Biotrial suspended the study on 11 January. In total, five participants were hospitalized, and the first participant later became brain-dead. The event raised serious questions about first-in-human trial management, dose escalation, communication, and clinical oversight. BIA 10-2474 did not become a commercial product. Bial’s public history therefore contains two contrasting themes: the emergence of a Portuguese company capable of discovering and licensing internationally used medicines, and the substantial safety, governance, and reputational consequences associated with a failed experimental clinical program. The company has nevertheless remained active as an internationally operating pharmaceutical business. In 2024, it received honorary membership of the Military Order of Saint James of the Sword, a Portuguese distinction recognizing its standing in national public life.

1. 2024Honorary membership of the Military Order of Saint James of the Sword

   Bial receives honorary membership of the Portuguese Military Order of Saint James of the Sword.

   Source
2. 2016BIA 10-2474 trial halted

   A first-in-human multiple-dose study of BIA 10-2474 in Rennes is suspended after serious neurological adverse events and hospitalizations.

   Source
3. 2015European Investment Bank R&D agreement

   The European Investment Bank signs a €45 million, three-year financing agreement supporting Bial’s research in central nervous system disorders, cardiology, and allergen immunotherapy.

   Source
4. 2015Anamorelin licensing agreement with Helsinn

   Bial enters an agreement granting Helsinn Group exclusive distribution and licensing rights for anamorelin in four Portuguese- and Spanish-linked markets.

   Source
5. 2008Clinical evaluation of eslicarbazepine acetate completed

   Bial completes clinical evaluation of eslicarbazepine acetate for adjunctive treatment of partial seizures in adults with epilepsy.

   Source
6. 1924Bial is founded in Portugal

   Bial is established and begins the corporate history that would lead to its position as one of Portugal’s major pharmaceutical companies.

   Source

A Portuguese research-led pharmaceutical company with an international licensing and commercialization footprint, particularly associated with central-nervous-system medicines and specialist therapies.

• Eslicarbazepine acetateAntiseizure medicine

  Eslicarbazepine acetate is an antiseizure medicine developed for adjunctive treatment of partial-onset seizures in adults with epilepsy. Bial completed its clinical evaluation in 2008 and licensed regional commercialization rights to international partners. Eisai marketed it in Europe as Zebinix or Exalief, while Sunovion marketed it in the United States as Aptiom. Additional pediatric development was pursued, and a separate study in diabetic neuropathic pain was discontinued prematurely.

• OpicaponeParkinson’s disease medicine

  Opicapone, identified in Bial’s research history as BIA 9-1067, is a catechol-O-methyltransferase inhibitor developed for Parkinson’s disease. It represents one of Bial’s principal neurological pharmaceutical programs and extends the company’s research focus beyond epilepsy into movement disorders.

• EtamicastatCardiovascular and autonomic-system research compound

  Etamicastat, also known as BIA 5-453, is a dopamine-beta-hydroxylase inhibitor investigated for its ability to lower norepinephrine levels in peripheral sympathetically innervated tissues without comparable effects in brain tissue. It was part of Bial’s cardiovascular and autonomic pharmacology research portfolio.

• BIA 5-1058Dopamine-beta-hydroxylase inhibitor

  BIA 5-1058 is a reversible dopamine-beta-hydroxylase inhibitor investigated for peripheral reduction of norepinephrine activity without central nervous system effects. Publicly described research associated the compound with Bial’s cardiovascular and autonomic therapeutic interests.

• BIA 10-2474FAAH inhibitor

  BIA 10-2474 was an experimental fatty-acid amide hydrolase inhibitor intended to modulate the endocannabinoid system. A phase-one trial conducted by Biotrial in Rennes was stopped in January 2016 after severe neurological adverse events among participants receiving multiple doses. The compound did not become a commercial medicine.

• 2015Secure institutional financing for research expansionStrategy

  Bial sought support for research programs in central nervous system disorders, cardiology, and allergen immunotherapy.

  What changed. The company entered a €45 million, three-year research and development financing agreement with the European Investment Bank.

  Aftermath. The agreement provided external support for Bial’s research-led international pharmaceutical strategy.

  Research and development financing. €45 million committed (Three years from September 2015)

  Source
• 2015License and distribution partnership for anamorelinM&A

  Bial expanded its regional portfolio through an external licensing and distribution relationship.

  What changed. Bial agreed with Helsinn Group to grant exclusive distribution and licensing rights for anamorelin in Spain, Portugal, Angola, and Mozambique.

  Aftermath. The agreement broadened the parties’ commercial reach for the product in selected Iberian and Lusophone markets.

  Source

• 2016BIA 10-2474 first-in-human clinical-trial incidentControversy

  A multiple-dose phase-one trial of Bial’s experimental FAAH inhibitor BIA 10-2474, conducted by Biotrial in Rennes, was suspended after the first participant was hospitalized and five participants in total required hospitalization. The first participant later became brain-dead. The incident prompted scrutiny of the trial’s dose escalation, monitoring, sponsor and contract-research-organization responsibilities, and the broader governance of early-stage human drug testing.

  Source

• 2024Bial receives honorary membership of the Military Order of Saint James of the Sword

  Bial was awarded honorary membership of Portugal’s Military Order of Saint James of the Sword.

  Other
  Source
• 2015European Investment Bank agrees €45 million R&D financing for Bial

  The European Investment Bank signed a three-year, €45 million financing agreement supporting Bial research in central nervous system disorders, cardiology, and allergen immunotherapy.

  Other
  Source
• 2015Bial and Helsinn Group sign anamorelin licensing and distribution agreement

  Bial granted Helsinn Group exclusive distribution and licensing rights for anamorelin in Spain, Portugal, Angola, and Mozambique.

  M&A
  Source

1. Bial
2. Bial official website